Analyst Insights

Argus Reiterates Buy On Duke Energy; Sees %16 Upside For The Stock

In a research report released today, Argus analyst Gary Hovis maintained coverage with a Buy rating on shares of Duke Energy Corporation (DUK), and a price target of $83, which implies a potential …

Analyst Vs. Analyst: Blackberry – Who Do You Side With?

Today we are going to be having an analyst versus analyst special, featuring Cormark Security analyst, Richard Tse versus Macquarie analyst Kevin Smithen for Blackberry (BBRY), a Canadian …

Argus Maintains Hold On Fortune Brands As Shares Are Fairly Valued

In a research report issued today, Argus analyst Chris Graja maintained coverage with a Hold rating on shares of Fortune Brands (FBHS), as he believes that the shares are fairly valued …

Argus Maintains Hold On McKesson As The Stock Price Incorporates All Major Drivers

In a research report issued this morning, Argus analyst David Toung maintained coverage with a Hold rating on shares of McKesson Corporation (MCK). No price target was assigned.

Argus Maintains Buy On Danaher In Light Of Strong Quarter And Future Acquisition Potential

In a research report issued this morning, Argus analyst Jim Kelleher maintained coverage with a Buy rating on shares of Danaher Corp. (DHR), with a target price of $86, which represents a potential …

AECOM: Shares Are Attractively Valued At Prices In The Low $30s, Says Argus

In a research note released today, Argus analyst John Eade maintained a Buy rating on shares of AECOM Technology Corporation (ACM), with a fair value of $38 per share. “We …

PTC Therapeutics Remains Well Positioned With A Broad Clinical Pipeline, Says Roth Capital

In a research report released this morning, Roth Capital analyst Debjit Chattopadhyay initiated coverage on shares of PTC Therapeutics (PTCT). He issued a Buy …

Roth Capital Invites Clients For Booth Tours At The 2014 Intersolar North America Conference

Roth Capital, lead by analyst Philip Shen, is hosting two days of booth tours at the 2014 Intersolar North America conference on July …

Roth Capital Sees 90% Probability Of BioDelivery’s Buprenorphine Approval

In a research note released this morning, Roth Capital analyst Scott Henry maintained a Buy rating on BioDelivery Sciences (BDSI) and raised his price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts